Iron overload is one of the major causes of morbidity in patients with thalassemia major. Deferiprone (DFP), an orally active iron chelator, emerged from an extensive search for new drugs to treat iron overload. Comparative studies have shown that at comparable doses the efficacy of DFP in removing body iron is similar to that of desferoxamine (DFO). In retrospective and prospective studies, DFP monotherapy was significantly more effective than DFO in the treatment of myocardial siderosis in thalassemia major. DFP can be used in combination with DFO in the management of severe iron overload. This chelation regimen is tolerable and attractive for patients unable to comply with standard DFO infusions or with inadequate response to DFP monotherapy. DFP has a well-known long-term safety profile. Agranulocytosis is the most serious side effect associated with its use, occurring in about 1% of the patients. More common but less serious side effects are gastrointestinal symptoms, arthralgia, zinc deficiency, and fluctuating transaminase levels.

Keywords:
Chelation, Combination therapy, Deferiprone, Gastrointestinal symptoms, Myocardial siderosis, Thalassemia major
1.
Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV: 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;i: 1294–1295.
2.
Kontoghiorghes GJ: New orally active iron chelators. Lancet 1985;i:817.
3.
Hoffbrand AV: Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005;18:299–317.
4.
Andrews NC: Disorders of iron metabolism. N Engl J Med 1999;341:1986–1995.
5.
Hershko C, Graham G, Bates GW, Rachmilewitz EA: Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978;40:255–263.
6.
Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P: LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005;18:277–287.
7.
Rund D, Rachmilewitz E: Beta-thalassemia. N Engl J Med 2005;353:1135–1146.
8.
Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574–578.
9.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187–1193.
10.
Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR: Complications of beta-thalassemia major in North America. Blood 2004;104:34–39.
11.
Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455–3462.
12.
Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D: Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006;91:1343–1351.
13.
Clarke ET, Martell AE: Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions. Inorg Chim Acta 1992;191:57–63.
14.
Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M: Iron chelator research: past, present, and future. Curr Med Chem 2003;10:983–995.
15.
Matsui D, Klein J, Hermann C, Grunau V, McClelland R, Chung D, St-Louis P, Olivieri N, Koren G: Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991;50:294–298.
16.
Al-Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV: Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995;89:403–408.
17.
Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L: Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 1987;295:1509–1512.
18.
Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P: Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990;76:295–300.
19.
Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT: Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460–466.
20.
Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF: Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329–2333.
21.
Grady RW, Berdoukas VA, Rachhmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V, Sitarou M, Hadjigavriel M, Giardina PJ: Exploring the shuttle effect: implications for combined chelator treatment (abstract). Santorini, Proc 12th Int Conf Oral Chelation in the Treatment of Thalassemia and Other Diseases, 2002, pp 62–63.
22.
Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17–24.
23.
Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM: Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275–1279.
24.
Maggio A, D’Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D’Ascola DG, Rizzo A, Midiri M: Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002;28:196–208.
25.
Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F: Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001;67:30–34.
26.
Piga A, Gaglioti C, Fogliacco E, Tricta F: Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003;88:489–496.
27.
Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH: Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003;70:392–397.
28.
Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187–1193.
29.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ: Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171–2179.
30.
Westwood MA, Anderson LJ, Firmin DN, Gatehouse PD, Lorenz CH, Wonke B, Pennell DJ: Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia. J Magn Reson Imaging 2003;18:616–620.
31.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ: Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516–520.
32.
Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A, Malizia R, Borsellino Z, Capra M, D’Ascola DG, Magnano C, Gerardi C, Rigano P, Maggio A: Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 2003;27:63–76.
33.
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R: Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107:3738–3744.
34.
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A: Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733–3737.
35.
Hider RC, Liu ZD: Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload. Curr Med Chem 2003;10:1051–1064.
36.
Wonke B, Wright C, Hoffbrand AV: Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361–364.
37.
Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A: Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187–189.
38.
Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R: Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005;90:1309–1314.
39.
Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C: Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 2003;88:1423–1425.
40.
Daar S, Pathare AV: Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol 2006;85:315–319.
41.
Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ: A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876–1884.
42.
Wu KH, Chang JS, Tsai CH, Peng CT: Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004;83:471–473.
43.
Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A: Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005;74:84–85.
44.
Porcu M, Landis N, Salis S, Corda M, Orrù P, Serra E, Usai B, Matta G, Galanello R: Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report. Eur J Heart Fail 2007;9:320–322.
45.
Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G: Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 2006;91(6 suppl):ECR19.
46.
Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ: Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12.
47.
Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD: Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007;109:362–364.
48.
Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G: Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006;134:438–444.
49.
Christoforidis A, Perifanis V, Athanassiou-Metaxa M: Combined chelation therapy improves glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006;135:271–272.
50.
Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M: Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica 2006;91:1187–1192.
51.
Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F: A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006;91:1241–1243.
52.
Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D’Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D’Amico G, Morabito A, Gluud C: Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009;145:245–254.
53.
Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D‘Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P: Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009;42:247–251.
54.
Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F: Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583–1587.
55.
Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefàno I, Tricta F: The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330–336.
56.
Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995;91:224–229.
57.
El-Beshlawi A, Sari TT, Chan LL, Tricta F, El-Alfy M: The safety and efficacy of an oral solution formulation of deferiprone in children with transfusional iron overload (abstract). Singapore, 11th International Conference on Thalassaemia and hemoglobinopathies and 13th International TIF Conference for Thalassaemia Patients and Parents, October 8–11, 2008.
58.
Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918–922.
59.
Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F: Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;108:305–312.
60.
Choudhry VP, Pati HP, Saxena A, Malaviya AN: Deferiprone, efficacy and safety. Indian J Pediatr 2004;71:213–216.
61.
Olivieri NF, Brittenham GM: Long-term trials of deferiprone in Cooley’s anemia. Ann NY Acad Sci 1998;850:217–222.
62.
Kowdley KV, Kaplan MM: Iron-chelation therapy with oral deferiprone – toxicity or lack of efficacy? N Engl J Med 1998;339:468–469.
63.
Callea F: Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998;339:1710–1711.
64.
Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295–300.
65.
Piga A, Longo F, Voi V, Facello S, Miniero R, Dresow B: Late effects of bone marrow transplantation for thalassemia. Ann NY Acad Sci 1998;850:294–299.
66.
Galanello R, De Virgiliis S, Agus A: Sequential liver fibrosis grading during deferiprone treatment in patients with thalassemia major (abstract). Hamburg, 9th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Diseases, March 25–28, 1999, p 50.
67.
Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR: Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566–1569.
68.
Berdoukas V, Bentley P, Frost H, Schnebli HP: Toxicity of oral iron chelator L1. Lancet 1993;341:1088.
69.
Goudsmit R, Kersten MJ: Long-term treatment of transfusion hemosiderosis with the oral iron chelator L1. Drugs Today 1992;28:133–135.
70.
Kersten MJ, Lange R, Smeets ME, Vreugdenhil G, Roozendaal KJ, Lameijer W, Goudsmit R: Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996;73:247–252.
71.
Gogtay JA, Agarwal MB: Clinical experience with Kelfer (deferiprone) in India over the last 12 years (abstract). Santorini, 12th International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases, 2002, p 89.
72.
Magnano C, Caruso V, Caruso M, Anastasi S: Two cases of healthy children born thalassemic patients treated with L1. Bangkok, 7th International Conference on Thalassemia and the Haemoglobinopathies, 1999.
73.
Müller A, Soyano A, Soyano-Müller A: Irreversible aplastic anemia after treatment with deferiprone in a patient with blackfan diamond anemia and hemochromatosis (abstract). Blood 2000;96:13b.
74.
Apotex Research: Ferriprox: Periodic Safety Update Report, PSUR. Toronto, Apotex, 2003.
75.
Whitnall M, Richardson DR: Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 2006;13:186–197.
76.
Molina-Holgado F, Hider RC, Gaeta A, Williams R, Francis P: Metals ions and neurodegeneration. Biometals 2007;20:639–654.
77.
Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI: Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110:401–408.
78.
Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R: Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008;23:904–907.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.